Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aussie Nurses Allegedly Paid To Find Patients For Merck’s Vioxx, Court Told

This article was originally published in PharmAsia News

Executive Summary

Australian nurses were allegedly paid by U.S.-based Merck and its Australian subsidiary, Merck, Sharp and Dohme to find prospective patients for the Vioxx (rofecoxib) anti-arthritis drug. That revelation was presented in a continuing class-action suit against the drug maker. The court was told Merck paid the nurses to get a physician's permission to go through his patient records and interview patients about their condition and pain management. Earlier, the court heard that pharmacists were paid by Merck to recommend to patients they take Vioxx instead of other drugs, such as paracetamol. (Click here for more

You may also be interested in...

Cosmetic And Personal Care Trademark Review 20 October, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

With $850m, Nuvation Aims To Speed Novel Cancer Drugs To Patients

Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts